Dr. Spencer has received grants from, is a member of the speakers bureau for, and is a consultant for Ortho-McNeil, Alza, Celltech, GlaxoSmithKline, Lilly, National Institute of Mental Health, Novartis, Pfizer, and Shire.

 

 

Dr. Adler is a consultant for Celgene, Novartis, Lilly, Ortho-McNeil, and Shire; has received grant/research support from Celgene, Lilly, Pfizer, Novartis, and GlaxoSmithKline; and has received honoraria from GlaxoSmithKline, Lilly, Ortho-McNeil, Pfizer, and Novartis.

 

 

Dr. Barkley has received royalties from Guilford Press.

 

 

Dr. Mason is a consultant for Lilly.

 

 

Dr. Roth has no financial or other relationships with any organization or entity to disclose.

 

 

 

 

 

Dr. Spencer has received grants from, is a member of the speakers bureau for, and is a consultant for Ortho-McNeil, ALZA, Celltech Medieva, GlaxoSmithKline, Lilly, National Institute of Mental Health, Novartis, Pfizer, and Shire.

 

 

 

 

Dr. Barkley has received royalties from Guilford Press.

 

 

 

 

Dr. Kratochvil is a consultant for Lilly, Shire, and ALZA; has received grant/research support from Lilly, Ortho-McNeil, and GlaxoSmithKline; has received honoraria from Lilly; and is a speaker for or is on the advisory board for Lilly and Novartis.

 

 

 

 

Dr. Saylor is a consultant for Lilly and has received honoraria from Physicians Postgraduate Press.

 

 

 

 

Dr. Wernicke is an employee of Lilly.

 

 

 

 

Dr. Wolraich is a consultant for Lilly, Cell-Tech, and Noven; has received grant/research support from Noven; and is a speaker for or is on the advisory board for National Initiative for Children's Healthcare Quality, American Board of Pediatrics, and Advanced Therapeutic Communications.

 

 

 

 

Dr. Buermeyer has no financial or other relationships with any organization or entity to disclose.

 

 

 

 

 

 

 

Dr. Jain is a consultant for Eli Lilly and GlaxoSmithKline; has received grant/research support from Wyeth, GlaxoSmithKline, Eli Lilly, and Merck; has received honoraria from Wyeth, GlaxoSmithKline, and Eli Lilly; and is a member of the speakers/advisory board for Eli Lilly.

 

 

 

 

 

 

 

 

 

 

 

Dr. Duesenberg is a consultant for and has received honoraria from Eli Lilly and Shire Richwood; has received grant/research support from Eli Lilly, Shire Richwood, Novartis, and Johnson & Johnson; and is a member of the speakers/advisory boards for Eli Lilly, Shire Richwood, and Forest.

 

 

 

 

 

 

 

 

 

 

Dr. Donnelly is an employee of Dartmouth Medical School; is a consultant for Eli Lilly and Pfizer; has received grant/research support from Janssen, Pfizer, and Eli Lilly; has received honoraria from GlaxoSmithKline and AstraZeneca; and is a member of the speakers/advisory boards for Eli Lilly, Pfizer, Janssen, and GlaxoSmithKline.

 

 

 

 

 

 

 

 

 

 

 

Dr. Biederman has received research support from Shire Richwood, Eli Lilly, Wyeth, Pfizer, Cephalon, Novartis, Janssen, Noven Pharmaceutical, Stanley Foundation, the National Institute of Mental Health (NIMH), the National Institute of Child Health & Human Development, and the National Institute on Drug Abuse (NIDA); is a member of the speakers bureaus for GlaxoSmithKline, Eli Lilly, Pfizer, Novartis, Wyeth, Shire Richwood, ALZA, and Cephalon; and is a member of the advisory boards for Eli Lilly, Celltech, Shire Richwood, Novartis, Noven Pharmaceutical, ALZA, McNeil, and Cephalon.

 

 

 

 

 

 

 

 

 

 

Dr. Adler is a consultant for, has received grant/research support and honoraria from, and is a member of the speakers or advisory boards for Novartis, Abbott, Eli Lilly, Pfizer, Merck, McNeil, and Johnson & Johnson.

 

 

 

 

 

 

 

 

 

 

Dr. Culpepper is a consultant for Forest, Cephalon, Janssen, Eli Lilly, Pfizer, and Wyeth.

 

 

 

 

 

 

 

 

 

 

 

 

Dr. Mason is a consultant for and a member of the speakers/advisory board of Eli Lilly.

 

 

 

 

 

 

 

 

 

 

Dr. Montano is a consultant for Eli Lilly, GlaxoSmithKline, Organon, Forest, Roche, and Wyeth; has received grant/research support from Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline; and has received honoraria from and is a member of the speakers or advisory boards for Eli Lilly, GlaxoSmithKline, Forest, Organon, and Wyeth.

 

 

 

 

 

 

 

 

 

Dr. Roth is a consultant for Eli Lilly.

 

 

 

 

 

 

 

 

 

 

 

Dr. Spencer has received research support from Abbott, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Celltech, Novartis, Pfizer, Shire Richwood, and Wyeth; is a member of the speakers bureaus of Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Celltech, Novartis, Shire Richwood, and Wyeth; and is a consultant for Eli Lilly, GlaxoSmithKline, Janssen, McNeil, Novartis, Pfizer, and Shire Richwood.

 

 

 

 

 

 

 

 

 

 

Dr. Weiss has received grant/research support from Circa Dia and Eli Lilly and is a consultant for, has received honoraria from, and is a member of the speakers or advisory boards of Eli Lilly, GlaxoSmithKline, Circa Dia, Shire Richwood, Novartis, Purdue Pharma, and Janssen.

 

 

 

 

 

 

 

 

 

Dr. Wilens is a consultant for, has received grant/research support from, and is a member of the speakers bureaus of Abbott, Celltech, Eli Lilly, McNeil, National Institute on Drug Abuse (NIDA), National Institute of Mental Health (NIMH), Novartis, Pfizer, Shire Richwood, and GlaxoSmithKline.

 

 

 

 

 

 

 

 

 

 

Dr. Murphy has no financial relationships to disclose significant to the presentation.